Literature DB >> 2988621

The mechanism for inhibition of gastric (H+ + K+)-ATPase by omeprazole.

P Lorentzon, B Eklundh, A Brändström, B Wallmark.   

Abstract

Omeprazole was found to inhibit the K+-stimulated ATPase activity of the gastric (H+ + K+)-ATPase in parallel with the K+-stimulated p-nitrophenylphosphatase activity and the phosphoenzyme formation. The degree of inhibition of ATPase activity was directly correlated to the amount inhibitor bound to the enzyme preparation down to about 15% of the control enzyme activity. The acid-decomposed form of omeprazole, i.e. the inhibitory form, was found to react with and bind to sulfhydryl groups within the (H+ + K+)-ATPase preparation with close to a 1:1 stoichiometry. beta-Mercaptoethanol, when added beforehand and in a 10-fold excess of omeprazole, completely prevented binding of the inhibitor and its inhibition of the enzyme. In the presence of beta-mercaptoethanol two different reaction products could be detected in addition to omeprazole; the reduced form of omeprazole (H 168/22), and a product formed between beta-mercaptoethanol and a decomposition product, generated from omeprazole. Under those conditions neither inhibition nor binding was obtained, indicating that none of these three compounds was the inhibitor. Rather, the compound generated from omeprazole and reacting rapidly with either beta-mercaptoethanol or the -SH groups of the enzyme was the likely inhibitor compound. In order to reverse already established inhibition higher concentrations of beta-mercaptoethanol were needed than for protection indicating two different reaction pathways for protection and reversal by beta-mercaptoethanol. The reversal reaction was explained by a two-step reaction; in the first step the bound inhibitor was exchanged for a beta-mercaptoethanol molecule resulting in formation of compound H 168/22 and a mixed disulfide between the enzyme and beta-mercaptoethanol. In the second step, attack of another beta-mercaptoethanol molecule results in liberation of active enzyme and generation of the disulfide form of beta-mercaptoethanol. This hypothesis was substantiated by the fact that when 1 mM beta-mercaptoethanol was added to inhibited enzyme the radiolabel was partially displaced, without any change in the concentration of modified -SH groups.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 2988621     DOI: 10.1016/0005-2736(85)90064-1

Source DB:  PubMed          Journal:  Biochim Biophys Acta        ISSN: 0006-3002


  9 in total

1.  Pharmacokinetic study of omeprazole in elderly healthy volunteers.

Authors:  S Landahl; T Andersson; M Larsson; B Lernfeldt; P Lundborg; C G Regårdh; E Sixt; I Skånberg
Journal:  Clin Pharmacokinet       Date:  1992-12       Impact factor: 6.447

2.  Madin-Darby canine kidney cells. III. Aldosterone stimulates an apical H+/K+ pump.

Authors:  H Oberleithner; W Steigner; S Silbernagl; U Vogel; G Gstraunthaler; W Pfaller
Journal:  Pflugers Arch       Date:  1990-07       Impact factor: 3.657

3.  Active potassium absorption in rat distal colon.

Authors:  J H Sweiry; H J Binder
Journal:  J Physiol       Date:  1990-04       Impact factor: 5.182

Review 4.  Functional domains of the gastric HK ATPase.

Authors:  G Sachs; K Munson; V N Balaji; D Aures-Fischer; S J Hersey; K Hall
Journal:  J Bioenerg Biomembr       Date:  1989-10       Impact factor: 2.945

Review 5.  Omeprazole. A preliminary review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in peptic ulcer disease and Zollinger-Ellison syndrome.

Authors:  S P Clissold; D M Campoli-Richards
Journal:  Drugs       Date:  1986-07       Impact factor: 9.546

6.  The effects of varying acidity on Helicobacter pylori growth and the bactericidal efficacy of ampicillin.

Authors:  E A Marcus; N Inatomi; G T Nagami; G Sachs; D R Scott
Journal:  Aliment Pharmacol Ther       Date:  2012-09-25       Impact factor: 8.171

7.  Omeprazole (40 mg) is superior to ranitidine in short-term treatment of ulcerative reflux esophagitis.

Authors:  G Vantrappen; L Rutgeerts; P Schurmans; J L Coenegrachts
Journal:  Dig Dis Sci       Date:  1988-05       Impact factor: 3.199

8.  Pharmacokinetics of [14C]omeprazole in patients with liver cirrhosis.

Authors:  T Andersson; R Olsson; C G Regårdh; I Skånberg
Journal:  Clin Pharmacokinet       Date:  1993-01       Impact factor: 6.447

9.  Molecular mechanism of inhibition of the mitochondrial carnitine/acylcarnitine transporter by omeprazole revealed by proteoliposome assay, mutagenesis and bioinformatics.

Authors:  Annamaria Tonazzi; Ivano Eberini; Cesare Indiveri
Journal:  PLoS One       Date:  2013-12-09       Impact factor: 3.240

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.